InterMune drug may offer big upside to Roche if aimed at liver

August 27, 2014 11:12 PM

9 0

InterMune drug may offer big upside to Roche if aimed at liver

(Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

Industry analysts have forecast annual sales of about $2 billion for the pulmonary fibrosis treatment, pirfenidone, once it gains U.S. approval, giving Roche a valuable addition to its respiratory franchise.

Also watch: First ‘Spider-Man: Homecoming’ trailer bounds with strong new promise for the Sony franchise

Read more

To category page

Loading...